| David Lawrence Fahey, DO | |
|
1600 1st St E, Independence, IA 50644-3155 | |
| (319) 332-0999 | |
| Not Available |
| Full Name | David Lawrence Fahey |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 1600 1st St E, Independence, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467833632 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R-10379 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cedar Valley Hospice | Waterloo, IA | Hospice |
| Buchanan County Health Center | Independence, IA | Hospital |
| Abcm Rehab Centers Of Independence West Campus | Independence, IA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peoples Memorial Hospital | 9931010790 | 41 |
News Archive
Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).
The Hematology/Oncology Pharmacy Association (HOPA) will present the HOPA Oncology Pharmacy Practice Management Program at the Hilton Rosemont/Chicago O'Hare on September 18-19, 2015, in Rosemont, IL.
New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.
› Verified 6 days ago
| Entity Name | Peoples Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336281245 PECOS PAC ID: 9931010790 Enrollment ID: O20031118000161 |
News Archive
Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).
The Hematology/Oncology Pharmacy Association (HOPA) will present the HOPA Oncology Pharmacy Practice Management Program at the Hilton Rosemont/Chicago O'Hare on September 18-19, 2015, in Rosemont, IL.
New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.
› Verified 6 days ago
| Entity Name | Broadlawns Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467447508 PECOS PAC ID: 3678466166 Enrollment ID: O20040206000913 |
News Archive
Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).
The Hematology/Oncology Pharmacy Association (HOPA) will present the HOPA Oncology Pharmacy Practice Management Program at the Hilton Rosemont/Chicago O'Hare on September 18-19, 2015, in Rosemont, IL.
New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.
› Verified 6 days ago
| Entity Name | Peoples Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518417518 PECOS PAC ID: 9931010790 Enrollment ID: O20161117001041 |
News Archive
Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).
The Hematology/Oncology Pharmacy Association (HOPA) will present the HOPA Oncology Pharmacy Practice Management Program at the Hilton Rosemont/Chicago O'Hare on September 18-19, 2015, in Rosemont, IL.
New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Lawrence Fahey, DO 1600 1st St E, Independence, IA 50644-3155 Ph: (319) 332-0999 | David Lawrence Fahey, DO 1600 1st St E, Independence, IA 50644-3155 Ph: (319) 332-0999 |
News Archive
Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).
The Hematology/Oncology Pharmacy Association (HOPA) will present the HOPA Oncology Pharmacy Practice Management Program at the Hilton Rosemont/Chicago O'Hare on September 18-19, 2015, in Rosemont, IL.
New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.
› Verified 6 days ago
William Joseph Schmitt, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 1st St E, Independence, IA 50644 Phone: 319-332-0999 | |
Kurt Anthony House, D.O.,F.P. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 1st St E, Independence, IA 50644 Phone: 319-334-2541 Fax: 319-334-7054 | |
Duane Donald Jasper, MD FP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 1st St E, Independence, IA 50644 Phone: 319-334-2541 Fax: 319-334-7054 | |
Dr. Ricky R Mccormick, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 1st St E, Independence, IA 50644 Phone: 319-334-2541 Fax: 319-334-7054 |